Asparaginase Erwinia chrysanthemi (NCT06317662)

Name: Asparaginase Erwinia chrysanthemi trial for Acute Leukemia of Ambiguous Lineage (NCT06317662)
Uploaded: 2026-10-31T05:35:31.384Z
Duration: 1 min 28 s
Description: Asparaginase Erwinia chrysanthemi trial for Acute Leukemia of Ambiguous Lineage (NCT06317662). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06317662.

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia: a one-minute explainerNCT063176621 min

Asparaginase Erwinia chrysanthemi trial for Acute Leukemia of Ambiguous Lineage (NCT06317662). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for infants diagnosed by 365 days with CD19-positive B-cell or qualifying ambiguous-lineage acute leukemia. Combined prenatal/postnatal age must exceed 36 weeks; Down syndrome excludes participation.

The idea: combine chemotherapy with blinatumomab, which links immune cells to leukemia. KMT2A-rearranged cases are randomized with or without venetoclax, which blocks a survival protein; non-rearranged cases receive no venetoclax. The initial safety cohort is closed. Researchers assess residual leukemia and safety.

This phase 2 study plans 153 patients. Erin Breese leads through the Children's Oncology Group; 116 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.